

Disclosure Statement

A Joint Working project between: The Academic Health Science Network for the North East and North Cumbria Limited and BRISTOL-MYERS SQUIBB PHARMACEUTICALS LTD

Name of Project:	Title: “Reducing Atrial Fibrillation (AF) related strokes, through the design and implementation of service improvement initiatives across the Southern Collaborative”
Project Overview:	<p>The project has been designed to Reduce Atrial Fibrillation (AF) related strokes through the optimisation of anticoagulation medicines. Local services will be enhanced through the implementation of service improvement initiatives designed to deliver sustained improvements in the AF care pathway, for patients who are registered in GP practices across the Southern Collaborative.</p> <p>The programme will focus on the delivery of four key project objectives, underpinned by the implementation of six project initiatives which will be designed to optimise the care and outcomes for patients who have been diagnosed with AF.</p>
Project Objectives:	<p>Objective 1 -Design, develop and Implement a local clinical pathway to reduce unwarranted clinical variation, improve clinical outcomes for patients and reduce AF related strokes for patients who have an existing diagnosis of AF.</p> <p>Objective 2 – Improve clinical confidence and knowledge of AF within the general practice clinical teams across the Southern Collaborative including treatment and management of the condition, engaging with GP practices to embed the Clinical Digital Resource Collaborative Tool (CDRC).</p> <p>Objective 3– Optimise the use of anticoagulation medicines to treat and control patients diagnosed with AF, in accordance with NICE Guidance; delivering targeted pharmacist and/or increased general practice nurse capacity within practices to improve and increase case finding and enhance care for patients.</p> <p>Objective 4 – Evaluate the project outcomes to develop a set of recommendations, key learnings for the future roll out and commissioning of AF services across the locality.</p>
Patient Benefits:	<ul style="list-style-type: none"> • Patients will benefit from the rapid implementation of the national guidance and best practice across the four clinical commissioning groups; • Increased numbers of patients will be identified through case finding, and appropriately anti-coagulated, reducing their risk of stroke; • It is anticipated that the patient awareness of Atrial Fibrillation (AF) along with their understanding of why and how to take their medicines will improve; • Patients registered at GP practices within the Southern Collaborative will have improved access to, and consistency of service provision for the treatment of Atrial Fibrillation.
Stakeholders:	<p>Parties to the agreement are :</p> <ul style="list-style-type: none"> • The Academic Health Science Network for the North East and North Cumbria Limited • Bristol-Myers Squibb Pharmaceutical Company Limited on behalf of the BMS/Pfizer Alliance. <p>Participating organisations which are collectively referred to as the ‘Southern Collaborative’ are:</p>

	<ul style="list-style-type: none"> • NHS Hartlepool and Stockton-On-Tees Clinical Group (HaST); • NHS South Tees Clinical Commissioning Group (South Tees); • NHS North Durham Clinical Commissioning Group (North Durham); • NHS Durham, Dales, Easington and Sedgefield Clinical Commissioning (DDES). <p>Participating organisations supporting the implementation of the project are:</p> <ul style="list-style-type: none"> • North of England Commissioning Support Unit
Timelines:	The project will commence in November 2019 for a period of 18 months in accordance with the signed joint working agreement.